A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: Effect of a 1:1 ratio

Journal of Pain and Symptom Management

Volumn 41, Issue 6, 2011, Pages 1098-1105

  Benítez Rosario, Miguel Angel ^a   Salinas Martín, Antonio ^a   González Guillermo, Toribio ^a   Feria, Manuel ^b  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

cancer pain; dose ratio; oral ketamine; Subcutaneous ketamine

Indexed keywords

KETAMINE; MIDAZOLAM;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PATIENT; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONFUSION; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; FEMALE; HALLUCINATION; HUMAN; INSOBRIETY; MALE; PAIN ASSESSMENT; SOMNOLENCE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACIAL PAIN; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; KETAMINE; MALE; MIDDLE AGED; NEOPLASMS; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 79957663477     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2010.08.017     Document Type: Article

References (38)

1. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999;86:1856-1866. (Pubitemid 29513057)
2. McGeeney BE. Adjuvant agents in cancer pain. Clin J Pain 2008;24:S14-S20. (Pubitemid 351556395)
3. Colleau S. The essential adjuvant analgesics for neuropathic pain. Cancer Pain Release 2002;15. Available from http://whocancerpain.wisc.edu/?q=node/170. Accessed August 2010.
4. Quibell R, Northern Region Palliative Care Physicians Group. Guidelines for using ketamine. Available from http://www.newcastle-hospitals.org.uk/ downloads/clinical-guidelines/PerioperativeandCriticalCare/ KETAMINEGUIDELINES2010.pdf. Accessed August 2010.
5. Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician 2007;10:493-500. (Pubitemid 46971302)
6. Benítez-Rosario MA, Feria M, Salinas-Martín A, Martínez-Castillo LP, Martín-Ortega JJ. A retrospective comparison of the dose ratio between subcutaneous and oral ketamine. J Pain Symptom Manage 2003;25:400-402. (Pubitemid 36506665)
7. Kotlinska-Lemieszek A, Luczak J. Subanesthetic ketamine: an essential adjuvant for intractable pain. J Pain Symptom Manage 2004;28:100-102. (Pubitemid 38970071)
8. Fitzgibbon EJ, Viola R. Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit. J Palliat Med 2005;8:49-57. (Pubitemid 40144251)
9. Mercadante S, Arcuri E, Tirelli W, Cassucio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-252.
10. Prommer E. Ketamine to control pain. J Palliat Med 2003;6:443-446. (Pubitemid 36807927)
11. Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 1999;17:296-300. (Pubitemid 29159973)
12. Jackson K, Ashby M, Martin P, et al. Burst ketamine for refractory cancer pain. An open label audit of 39 patients. J Pain Symptom Manage 2001;22:834-842. (Pubitemid 32884376)
13. Kannan TR, Saxena A, Bhatnagar S, Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002;23:60-65. (Pubitemid 34093884)
14. Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerine as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999;90:1528-1533. (Pubitemid 29254794)
15. Good P, Tullio F, Jackson K, Goodchild C, Ashby M. Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory ('triple-agent') therapy for episodes of acute on chronic pain. Intern Med J 2005;35:39-44. (Pubitemid 40254766)
16. Chong CC, Shug SA, Page-Sharp M, Ilett KF. Bioavailability of ketamine after oral or sublingual administration. Pain Med 2006;7:469.
17. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 1981;53:805-810. (Pubitemid 11044337)
18. Yanagihara Y, Ohtani M, Kariya S, et al. Stereoselective high-performance liquid chromatographic determination of ketamine and its active metabolite, norketamine, in human plasma. J Chromatogr B Biomed Sci Appl 2000;746:227-231. (Pubitemid 30657939)
19. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg F. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997;333:99-104. (Pubitemid 27380456)
20. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage 2000;20:358-373.
21. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 1999;81:85-93. (Pubitemid 29199904)
22. Holtman JR Jr, Crooks PA, Johnson-Hardy JK, et al. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 2008;90:676-685.
23. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003;97:1730-1739. (Pubitemid 37475130)
24. Raben T, Skjelbred P, Øye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther 1999;289:1060-1066. (Pubitemid 29191267)
25. Blonk MI, Koder BG, Van den Bernt PMLA, Huygen FJPM. Use of oral ketamine in chronic pain management: a review. Eur J Pain 2010;14:466-472.
26. Borsook D. Ketamine and chronic pain - going the distance. Pain 2009;145:271-272.
27. Dahan A, Olofsen E, Sigtermans M, et al. Population pharmacokinetic- pharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2010. DOI: 10.1016/j.ejpain.2010.06.016. [Epub ahead of print].
28. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999;82:111-125. (Pubitemid 29317524)
29. Slatkin NE, Rhiner M. Ketamine in the treatment of refractory cancer pain: case report, rationale and methodology. J Support Oncol 2003;1:287-293.
30. Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. J Pain Symptom Manage 1999;17:384-386. (Pubitemid 29239531)
31. Nikolajsen L, Hansen PO, Jensen TS. Oral ketamine therapy in the treatment of postamputation stump pain. Acta Anaesthesiol Scand 1997;41:427-429. (Pubitemid 27140317)
32. Furuhashi-Yonaha A, Iida H, Asano T, Takeda T, Dohi S. Short- and long-term efficacy of oral ketamine in eight chronic-pain patients. Can J Anaesth 2002;49:886-887. (Pubitemid 35460497)
33. Fisher K, Hagen NA. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report. J Pain Symptom Manage 1999;18:61-66. (Pubitemid 29344638)
34. Haines DR, Simon PG. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 1999;83:283-287. (Pubitemid 29479287)
35. Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 2008;9:253-257. (Pubitemid 351285422)
36. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007;69:810-812. (Pubitemid 46670224)
37. Chu PS, Ma WK, Wong SC, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 2008;102:1616-1622.
38. Storr TM, Quibell R. Can ketamine prescribed for pain cause damage to the urinary tract? Palliat Med 2009;23:670-672.